SF0166 Topical Ophthalmic Solution

DRUG2 trials

Sponsors

OcuTerra Therapeutics, Inc.

Conditions

Age-Related Macular DegenerationDiabetic Macular Edema

Phase 1

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

CompletedNCT02914639

OcuTerra Therapeutics, Inc.Age-Related Macular Degeneration

Start: 2016-10-05End: 2017-06-26Updated: 2023-06-07

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

CompletedNCT02914613

OcuTerra Therapeutics, Inc.Diabetic Macular Edema

Start: 2016-08-24End: 2017-05-16Updated: 2023-05-11